BNTX BioNTech SE

$105.16

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About BioNTech SE

BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.

Website: https://www.biontech.de

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1776985
Address
AN DER GOLDGRUBE 12, MAINZ, DE
Valuation
Market Cap
$23.74B
P/E Ratio
nan
PEG Ratio
0.04
Price to Book
1.08
Performance
EPS
$-3.13
Dividend Yield
—
Profit Margin
-24.20%
ROE
-3.36%
Technicals
50D MA
$104.15
200D MA
$105.23
52W High
$131.49
52W Low
$76.53
Fundamentals
Shares Outstanding
240M
Target Price
$141.79
Beta
1.08

BNTX EPS Estimates vs Actual

● Estimated
● Actual

BNTX News & Sentiment

Oct 02, 2025 • Zacks Commentary NEUTRAL
Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?
Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.
Oct 01, 2025 • Motley Fool SOMEWHAT-BULLISH
Why BioNTech Stock Jumped by Nearly 4% on Wednesday
The company's push deeper into a hot new technology, plus good news from a top collaborator, put the shine on its equity.
Sep 26, 2025 • Zacks Commentary SOMEWHAT-BULLISH
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
Sep 24, 2025 • Zacks Commentary SOMEWHAT-BULLISH
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
Sep 23, 2025 • GlobeNewswire NEUTRAL
BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025
MAINZ, Germany, September 23, 2025 ( GLOBE NEWSWIRE ) -- BioNTech SE ( Nasdaq: BNTX, "BioNTech" ) , alongside its artificial intelligence ( "AI" ) company InstaDeep Ltd. ( "InstaDeep" ) , will host its second AI Day, an edition of BioNTech's "Innovation Series", at 09:00 a.m. EDT ( 3:00 p.m.
Sep 22, 2025 • Motley Fool SOMEWHAT-BULLISH
Why BioNTech Stock Bumped Higher Today
Investors were cheered by two pieces of good news concerning the biotech's most famous product.
Sentiment Snapshot

Average Sentiment Score:

0.098
50 articles with scored sentiment

Overall Sentiment:

Neutral

BNTX Reported Earnings

Mar 10, 2025
Dec 31, 2024 (Pre market)
0.71 Surprise
  • Reported EPS: $1.08
  • Estimate: $0.37
  • Whisper: —
  • Surprise %: 188.8%
Nov 04, 2024
Sep 30, 2024 (Pre market)
2.58 Surprise
  • Reported EPS: $0.88
  • Estimate: $-1.70
  • Whisper: —
  • Surprise %: 151.8%
Aug 05, 2024
Jun 30, 2024 (Pre market)
-1.34 Surprise
  • Reported EPS: $-3.36
  • Estimate: $-2.02
  • Whisper: —
  • Surprise %: -66.3%
May 06, 2024
Mar 31, 2024 (Pre market)
-0.24 Surprise
  • Reported EPS: $-1.41
  • Estimate: $-1.17
  • Whisper: —
  • Surprise %: -20.5%
Mar 20, 2024
Dec 31, 2023 (Pre market)
-0.52 Surprise
  • Reported EPS: $1.90
  • Estimate: $2.42
  • Whisper: —
  • Surprise %: -21.5%
Nov 06, 2023
Sep 30, 2023 (Pre market)
0.77 Surprise
  • Reported EPS: $0.67
  • Estimate: $-0.10
  • Whisper: —
  • Surprise %: 770.0%
Aug 07, 2023
Jun 30, 2023 (Pre market)
0.17 Surprise
  • Reported EPS: $-0.79
  • Estimate: $-0.96
  • Whisper: —
  • Surprise %: 17.7%
May 08, 2023
Mar 31, 2023 (Pre market)
1.91 Surprise
  • Reported EPS: $2.05
  • Estimate: $0.14
  • Whisper: —
  • Surprise %: 1364.3%
Mar 27, 2023
Dec 31, 2022 (Pre market)
1.27 Surprise
  • Reported EPS: $9.26
  • Estimate: $7.99
  • Whisper: —
  • Surprise %: 15.9%

Financials